
Commentary|Videos|July 8, 2015
Nivolumab Compared to Docetaxel in Patients With NSCLC
Author(s)Karen Reckamp, MD
Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).
Advertisement
Karen Reckamp, MD, MS, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, Department of Medical Oncology and Therapeutics Research, discusses nivolumab (Opdivo) compared to docetaxel for the treatment of patients with non-small cell lung cancer (NSCLC).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































